Search
BioCryst Pharmaceuticals Inc
BCRXAdd to Watchlist
9.650USD
-0.350-3.50%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
2.45BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-3.50%
5 Days
+3.65%
1 Month
+8.31%
6 Months
+23.72%
Year to Date
+23.72%
1 Year
+7.70%
Key Figures
10.000Open
10.148High
4.86MVolume
LossP/E TTM
33.02P/E Dynamic
--Dividend TTM
1.91%Turnover Ratio
10.000Prev. Close
9.585Low
34.90MTurnover
LossP/E Static
-4.43P/B
0.00%Div Yield TTM
-96.92%ROA
11.31052wk High
0.46Volume Ratio
-88.88MNet Profit
254.01MShares
-1.7226EPS TTM
0.58Beta
--ROE
6.00052wk Low
5.63%Amplitude
96.56%Gross Margin
2.45BMarket Cap
7.31Reward/Risk
2.72%Risk Rate
TradingKey Stock Score of BioCryst Pharmaceuticals Inc
Currency: USD Updated: 2026-06-30Key Insights
BioCryst Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 17 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 21.80.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BioCryst Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
BioCryst Pharmaceuticals Inc Highlights
StrengthsRisks
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 163.97% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is -5.81, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 235.68M shares, increasing 2.71% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 326.75K shares of this stock.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
21.800
Target Price
+128.27%
Upside Space
BioCryst Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
BioCryst Pharmaceuticals Inc Info
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
Ticker SymbolBCRX
CompanyBioCryst Pharmaceuticals Inc
CEOGayer (Charles K)
Websitehttps://www.biocryst.com/
Related Instruments
-0.64%
-0.05%
-2.95%
-0.23%
-2.41%
-1.64%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
52271.500
+75.200 (+0.14%)
29790.900
-433.700 (-1.44%)
7477.000
-5.400 (-0.07%)
15354.000
-241.000 (-1.54%)
69451.000
-1405.000 (-1.98%)
6276.300
-50.700 (-0.80%)
68.028
-1.893 (-2.71%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4037.600
+30.320 (+0.76%)
FAQs
What is the current price of BioCryst Pharmaceuticals Inc (BCRX)?
The current price of BioCryst Pharmaceuticals Inc (BCRX) is 10.00.
What is the symbol of BioCryst Pharmaceuticals Inc?
The ticker symbol of BioCryst Pharmaceuticals Inc is BCRX.
What is the 52-week high of BioCryst Pharmaceuticals Inc?
The 52-week high of BioCryst Pharmaceuticals Inc is 11.31.
What is the 52-week low of BioCryst Pharmaceuticals Inc?
The 52-week low of BioCryst Pharmaceuticals Inc is 6.00.
What is the market capitalization of BioCryst Pharmaceuticals Inc?
The market capitalization of BioCryst Pharmaceuticals Inc is 2.54B.
Is BioCryst Pharmaceuticals Inc (BCRX) currently rated as Buy, Hold, or Sell?
According to analysts, BioCryst Pharmaceuticals Inc (BCRX) has an overall rating of Buy, with a price target of 21.80.
What is the Earnings Per Share (EPS TTM) of BioCryst Pharmaceuticals Inc (BCRX)?
The Earnings Per Share (EPS TTM) of BioCryst Pharmaceuticals Inc (BCRX) is 1.26.